TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04943055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization
Description: The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: YAG lacrimal duct laser combined with lacrimal duct catheter
Description: The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
Study: NCT03050528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
Study: NCT00586105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: 400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
Study: NCT03934385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Rehearsal
Description: After each exposure session, participants complete three rehearsal/retrieval exercises that involve viewing images of spiders and completing multiple-choice and free-response questions. Exercises involve retrieving information specific to the spider exposures, reflecting on the experience, and highlighting expectancy violation (i.e., that the participant's feared outcome did not occur).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure
Description: All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.
Study: NCT01069783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3309 in two different dosage levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3309 in two different dosage levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3309 in two different dosage levels for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3309 in two different dosage levels for the duration of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator once daily for the duration of the trial
Study: NCT02981394

Intervention type: PROCEDURE
Intervention: Bone Marrow Aspirate Concentrate Injection
Description: BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
Study: NCT00931151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postprandial metabolic and functional measures
Description: After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postprandial metabolic and functional measures
Description: After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
Study: NCT02798861

Intervention type: DEVICE
Intervention: Fibroscan 402/530
Description: Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.
Study: NCT02239666

Intervention type: OTHER
Intervention: NIS
Description: This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
Study: NCT04013347

Intervention type: PROCEDURE
Intervention: Rectal Resection
Description: Low Anterior Resection and Abdominoperineal Resection
Study: NCT03050528

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise
Description: Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
Study: NCT04013347

Intervention type: PROCEDURE
Intervention: Rectal Resection
Description: Low Anterior Resection and Abdominoperineal Resection

Intervention type: PROCEDURE
Intervention: Rectal Resection
Description: Low Anterior Resection and Abdominoperineal Resection
Study: NCT03050528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Participants will attend weekly group psychology sessions for an eight-week period. Each session will be two hours in duration and will delivered by a Senior Psychologist trained in Acceptance and Commitment Therapy (ACT). The sessions will feature an ACT treatment process that is designed to promote psychological flexibility through various methods including acceptance and values awareness. The overall aim is to promote behaviour change, enhancing patient engagement in meaningful activities and reducing pain-avoidant behaviours. There is an emphasis on mindfulness, experiential learning and the use of metaphor which is unique to ACT.
Study: NCT02604238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Enoxaparin (1mg) 100UI aXa/kg/sc \[LMWH\], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing \<50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).
Study: NCT01642030

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study: NCT02858518

Intervention type: OTHER
Intervention: questionnaires
Description: scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
Study: NCT01642030

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydromorphone
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydromorphone
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study: NCT00812305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402 300mg in healthy patients
Description: SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402 300mg in hepatically impaired patients
Description: SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
Study: NCT01642030

Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study: NCT03278808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine-Azithromycin (CQ/AZ)
Description: Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine (CQ)
Description: Chloroquine (CQ); 300 mg of CQ only given orally

Intervention type: DRUG
Group type: OTHER
Intervention: atovaquone-proguanil (Malarone®)
Description: All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
Study: NCT04297423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plenvu
Description: randomization 1:1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plenvu
Description: randomization 1:1
Study: NCT00425906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality of life

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quality of life
Study: NCT01234428

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic surgery
Description: Gastric banding
Study: NCT02325258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone call
Description: Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
Study: NCT00608387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic disease management Web-based software
Description: Participants will have access to remotely based medical providers through the use of the Web-based software.
Study: NCT03204045

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fentanyl
Description: 2 mL mixture of fentanyl with isotonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: 2 mL mixture of fentanyl with isotonic saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 2 mL mixture of oxycodone with isotonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 2 mL mixture of oxycodone with isotonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: isotonic saline 2 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: isotonic saline 2 mL
Study: NCT02030847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10\^8 transduced CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: As of June 2014, dose was reduced to a single dose of 1-5x10\^7 CART-19 cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: In the protocol amendment in November 2014, the dose remained 1-5 x 10\^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: In the protocol amendment in May 2015, the dose was changed to 1-5 x 10\^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10\^7), 30% on Day 2 (3x10\^7-1.5x10\^8), 60% on Day 3 (6x10\^7-3x10\^8).
Study: NCT02444884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237
Study: NCT03948815

Intervention type: OTHER
Group type: OTHER
Intervention: interventional birthing room
Description: The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interventional birthing room
Description: The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.
Study: NCT04501354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell
Description: Mesenchymal Stem Cell + NaCl 0,9% 2ml
Study: NCT03185910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCP education
Description: MBCP education involves mindfulness breathing and other skills with mindfulness meditations.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hospital-based antenatal education
Description: Hospital-based antenatal education involves all aspects of pregnancy, childbirth and postpartum.
Study: NCT00003588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5CMV-p53 gene

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Study: NCT05591456

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adjuvant radiotherapy
Description: Treatment schedule and delivery The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
Study: NCT01234428

Intervention type: PROCEDURE
Group type: OTHER
Intervention: gastric banding
Description: laparoscopic gastric banding
Study: NCT03185299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard preparation instructions
Description: The control arm will receive written instruction on preparing for a colonoscopy per standard of care
Study: NCT00904189

Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Standard of care given for treatment of cancer
Description: Subjects receiving a known dose of radiation during Total Body Irradiation.
Study: NCT00348569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 64 Channel VCT
Study: NCT04309955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pigtail catheter
Description: After inserting the chest tube, add a pigtail catheter into the posterior axillary lines of the 7th intercostal.
Study: NCT02475967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.The content of platform will be gathered from a multidisciplinary input of both medics (e.g. cardiologists) and paramedics (e.g. psychologists). Patients will also contribute to platform content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group patients receive conventional cardiac care alone.
Study: NCT02949778

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL-block
Description: Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: QL-block
Description: Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 3.75mg/ml administered in QL-block as active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Sodium chloride 9mg/mL administered in QL-Block as placebo
Study: NCT03550794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine Hydrochloride
Description: Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50ml of 0.9% NACL will serve as the placebo
Study: NCT00751972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartWare® VAS
Description: The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
Study: NCT00918697

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical debridement
Description: For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alcohol-assisted debridement
Description: For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
Study: NCT04207554

Intervention type: DEVICE
Intervention: Test Device-Strip Format
Description: Sponsor's investigational device

Intervention type: DEVICE
Intervention: Test Device-Strip Format
Description: Sponsor's investigational device

Intervention type: DEVICE
Intervention: Test Device-Cassette Format
Description: Sponsor's investigational device

Intervention type: DEVICE
Intervention: Test Device-Cassette Format
Description: Sponsor's investigational device

Intervention type: DEVICE
Intervention: Predicate Device
Description: Commercially available device

Intervention type: DEVICE
Intervention: Predicate Device
Description: Commercially available device